Accelerating enrollment with custom-tailored recruitment in immunology trials
Immunological diseases and disorders affect millions of people around the world, with a staggering rate of patients being immunocompromised.
From autoimmune diseases to allergen disorders, effective patient recruitment requires a personalized approach and expertise among various niche conditions.
0
patients enrolled
0
studies completed
0
sites coordinated
Our​ difference​
Immunology clinical trials require deep-rooted expertise among a tight-knit community
1nHealth takes full ownership of the enrollment process across this complex therapeutic area—making patient recruitment one less challenge for you and your team.
Immunology trials rely on recruitment partners who are flexible and experienced across a range of niche conditions. You also need reliable results that can scale.
Given the chronic nature of many immunological conditions, long-term follow-up is essential to evaluate the durability of treatment effects and long-term safety.
At 1nHealth, we own the enrollment process from beginning to end. We understand recruitment only ends at LPI, allowing you to act with urgency as you bring life-saving treatments to the public.
Your trial is unique, which means your recruitment solution should be too
- You rely on experts who understand complex I/E criteria and have experience with complex symptoms to ensure high-quality referrals
- You need a recruitment partner who understands how every step of the funnel works together to deliver results on time and under budget
- You demand diverse representation, especially within conditions that disproportionately affect specific populations
- You expect quick and efficient site support when trials are enrolling extremely large patient populations globally
Our expertise
Early Allergic Syndrome
Early Allergic Syndrome (EAS) refers to the onset of allergic reactions, typically in childhood, that are triggered by exposure to environmental allergens such as pollen, dust mites, mold, or pet dander.
EAS is characterized by symptoms like sneezing, nasal congestion, and itching, and can progress to more severe manifestations, including asthma and atopic dermatitis.
The condition involves a mediated immune response, leading to inflammation and hypersensitivity.
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent inflammation of the synovial joints, leading to pain, stiffness, swelling, and potential joint damage.
RA primarily affects women and commonly begins between the ages of 30 and 50.
The pathogenesis involves dysregulated immune responses, including the activation of T-cells and the production of pro-inflammatory cytokines. It can lead to systemic complications, including cardiovascular disease and osteoporosis.
Celiac disease
Celiac disease is a chronic autoimmune disorder triggered by the ingestion of gluten in genetically predisposed individuals.
It results in an inflammatory response in the small intestine, leading to villous atrophy, malabsorption, and a variety of gastrointestinal and extra-intestinal symptoms, including diarrhea, weight loss, fatigue, and dermatitis herpetiformis.
The disease is associated with specific genetic markers. Currently, the primary treatment is a lifelong gluten-free diet.
Our​ success​
"1nHealth's strong team delivers comprehensive metrics, creates effective data-driven recruitment ads, and demonstrates impressive agility—quickly implementing changes to ensure enrollment campaign success."
Sponsor
Early Allergen System Experience (EASE)
Type 2 Diabetes
Hover to reveal top creative
Healthy Adults Registry
COVID-19 Registry
Atherosclerotic Cardiovascular Disease (ACD)
Hover to reveal top creative
Our experience across other therapeutic areas
Your next trial is thoughtful, complex, and different. Your patient recruitment should be too.
From kick-off to last patient in, 1nHealth builds a reliable source of referred enrollments through proven recruitment programs and high-touch patient engagement.
Click each area to learn more.​
